{"id":"avacincaptad-pegol-sodium","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Conjunctival hemorrhage","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Increased IOP","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Choroidal neovascularization","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Punctate keratitis","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Retinal hemorrhage","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Vitreous floaters","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Ocular hypertension","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Blepharitis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Corneal abrasion","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Ocular or periocular infection","Uveitis"],"specialPopulations":{},"seriousAdverseEvents":[{"effect":"Endophthalmitis","drugRate":"1%","severity":"serious"},{"effect":"Retinal detachment","drugRate":"1%","severity":"serious"},{"effect":"Vitreous hemorrhage","drugRate":"1%","severity":"serious"},{"effect":"Optic ischemic neuropathy","drugRate":"1%","severity":"serious"},{"effect":"Vitritis","drugRate":"1%","severity":"serious"},{"effect":"Vitreal cells","drugRate":"1%","severity":"serious"},{"effect":"Photopsia","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[{"type":"Method of Use","number":"11491176","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2034-07-11"},{"type":"Method of Use","number":"11273171","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2034-07-11"},{"type":"Compound","number":"9617546","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2027-02-14"},{"type":"Method of Use","number":"8236773","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2026-11-11"},{"type":"Method of Use","number":"12016875","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2034-07-11"},{"type":"Compound","number":"7579456","applicant":"ASTELLAS PHARMA US INC","territory":"US","tradeName":"IZERVAY","expiryDate":"2027-02-14"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AVACINCAPTAD PEGOL SODIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:41:52.746995+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:41:52.746890+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:41:59.527847+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AVACINCAPTAD PEGOL SODIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:41:59.928728+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Complement C5 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:01.597987+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297889/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:01.247771+00:00"}},"offLabel":[],"timeline":[{"date":"2021-06-01","type":"Clinical Trial","milestone":"Phase 2b/3 trial initiation for AMD","regulator":"FDA"},{"date":"2022-09-15","type":"Clinical Data Release","milestone":"Top-line results from Phase 2b/3 trial for AMD","regulator":"FDA"}],"_dailymed":null,"aiSummary":"Avacincaptad pegol sodium is an investigational drug with no FDA approval or label. It is being studied for its potential in treating various ophthalmic conditions, particularly those involving the retina. The drug's mechanism of action involves inhibiting complement activation, which is a key component of the immune system that can contribute to inflammation and tissue damage. Despite promising preclinical and early clinical results, the drug is still in development, and its safety and efficacy profiles are not yet fully established. The lack of an FDA label indicates that it has not yet been approved for any specific use, and its commercial prospects remain uncertain.","ecosystem":[],"mechanism":{"target":"Complement C5","novelty":"First-in-class complement C3 inhibitor for ophthalmic conditions","modality":"Small Molecule","drugClass":"Complement Inhibitors","explanation":"","oneSentence":"","technicalDetail":"Avacincaptad pegol sodium specifically targets the C3 component of the complement system, preventing its cleavage into C3a and C3b, which are key mediators of the complement cascade. By inhibiting this step, the drug aims to reduce the downstream effects of complement activation, such as the formation of the membrane attack complex (MAC) and the release of pro-inflammatory cytokines."},"_scrapedAt":"2026-03-28T00:38:49.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":0,"launchDate":"Not applicable due to lack of approval","annualCostUS":null,"currentRevenue":0,"patientPopulation":"Estimated to be in the millions for AMD and DME","peakSalesEstimate":"Not available due to lack of approval"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:02.903457+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":["Aflibercept (Eylea) - Regeneron Pharmaceuticals","Ranibizumab (Lucentis) - Genentech","Brolucizumab (Beovu) - Novartis"],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Geographic atrophy secondary to age-related macular degeneration","diseaseId":"geographic-atrophy-secondary-to-age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":["Age-related Macular Degeneration (AMD)","Diabetic Macular Edema (DME)"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL4297889"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"AVACINCAPTAD PEGOL SODIUM","genericName":"AVACINCAPTAD PEGOL SODIUM","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"2023","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8236773","territory":"US","patent_type":"Method of Use","expiry_date":"2026-11-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9617546","territory":"US","patent_type":"Compound","expiry_date":"2027-02-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7579456","territory":"US","patent_type":"Compound","expiry_date":"2027-02-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11491176","territory":"US","patent_type":"Method of Use","expiry_date":"2034-07-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11273171","territory":"US","patent_type":"Method of Use","expiry_date":"2034-07-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12016875","territory":"US","patent_type":"Method of Use","expiry_date":"2034-07-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:02.903457+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":false,"score":2}}